References
Andersen, G., Meiffren, G., Famulla, S., Heise, T., Ranson, A.,
Seroussi, C., Eloy, R., Gaudier, M., Charvet, R., & Chan, Y. P. (2021).
ADO09, a co‐formulation of the amylin analogue pramlintide and the
insulin analogue A21G, lowers postprandial blood glucose versus insulin
lispro in type 1 diabetes. Diabetes, Obesity and Metabolism ,23 (4), 961-970.
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow,
T., & Hoogwerf, B. J. (2012). Efficacy of GLP-1 receptor agonists and
DPP-4 inhibitors: meta-analysis and systematic review. Clinical
therapeutics , 34 (6), 1247-1258. e1222.
Association, A. D. (2010). Diagnosis and classification of diabetes
mellitus. Diabetes Care , 33 (Supplement 1), S62-S69.
Bae, C. S., & Song, J. (2017). The role of glucagon-like peptide 1
(GLP1) in type 3 diabetes: GLP-1 controls insulin resistance,
neuroinflammation and neurogenesis in the brain. International
journal of molecular sciences , 18 (11), 2493.
Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M. L., Søndergaard, F. L.,
& Connor, A. (2021). Relationship between oral semaglutide tablet
erosion and pharmacokinetics: a pharmacoscintigraphic study.Clinical pharmacology in drug development , 10 (5), 453-462.
Balakrishnan, M., Sudarsanam, P., & Nethaji, D. (2021). Formulation and
Evaluation of Controlled-release matrix Vildagliptin tablets.International Journal of Clinical Pharmacokinetics and Medical
Sciences , 1 (2), 35-41.
Barnett, A. (2007). Exenatide. Expert opinion on pharmacotherapy ,8 (15), 2593-2608.
Barnett, A. H. (2011). Lixisenatide: evidence for its potential use in
the treatment of type 2 diabetes. Core evidence , 6 , 67.
[Record #118 is using a reference type undefined in this output
style.]
Blech, S., Ludwig-Schwellinger, E., Gräfe-Mody, E. U., Withopf, B., &
Wagner, K. (2010). The metabolism and disposition of the oral dipeptidyl
peptidase-4 inhibitor, linagliptin, in humans. Drug Metabolism and
Disposition , 38 (4), 667-678.
Bode, B. (2012). An overview of the pharmacokinetics, efficacy and
safety of liraglutide. Diabetes research and clinical practice ,97 (1), 27-42.
Boulton, D., Li, L., Frevert, E. U., Tang, A., Castaneda, L.,
Vachharajani, N. N., Kornhauser, D. M., & Patel, C. G. (2011).
Influence of renal or hepatic impairment on the pharmacokinetics of
saxagliptin. Clinical pharmacokinetics , 50 (4), 253-265.
Boulton, D. W. (2017). Clinical pharmacokinetics and pharmacodynamics of
saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clinical
pharmacokinetics , 56 (1), 11-24.
Bray, G. M. (2006). Exenatide. American journal of health-system
pharmacy , 63 (5), 411-418.
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015).
Albiglutide for treating type 2 diabetes: an evaluation of
pharmacokinetics/pharmacodynamics and clinical efficacy. Expert
Opinion on Drug Metabolism and Toxicology , 11 (9), 1493-1503.
Bruni, G., Ghione, I., Berbenni, V., Cardini, A., Capsoni, D., Girella,
A., Milanese, C., & Marini, A. (2021). The Physico-Chemical Properties
of Glipizide: New Findings. Molecules , 26 (11), 3142.
Burness, C. B. (2015). Omarigliptin: first global approval.Drugs , 75 (16), 1947-1952.
Burness, C. B., & Scott, L. J. (2015). Dulaglutide: a review in type 2
diabetes. BioDrugs , 29 (6), 407-418.
Bush, M., Scott, R., Watanalumlerd, P., Zhi, H., & Lewis, E. (2012).
Effects of multiple doses of albiglutide on the pharmacokinetics,
pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral
contraceptive. Postgraduate medicine , 124 (6), 55-72.
Ceriello, A., De Nigris, V., Iijima, H., Matsui, T., & Gouda, M.
(2019). The unique pharmacological and pharmacokinetic profile of
teneligliptin: implications for clinical practice. Drugs ,79 (7), 733-750.
Chavan, K. H., Kedar, N., & Jadhav, R. I. (2020). An overview of recent
development towards the synthesis of Linagliptin a DPP-4 inhibitor.Chemistry & Biology Interface , 10 (5).
Chia, C. W., & Egan, J. M. (2020). Incretins in obesity and diabetes.Annals of the New York Academy of Sciences , 1461 (1),
104-126.
Cho, Y. M., Deerochanawong, C., Seekaew, S., Suraamornkul, S.,
Benjachareonwong, S., Sattanon, S., Chamnan, P., Sirirak, T.,
Kosachunhanun, N., & Pratipanawatr, T. (2020). Efficacy and safety of
gemigliptin as add‐on therapy to insulin, with or without metformin, in
patients with type 2 diabetes mellitus (ZEUS II study). Diabetes,
Obesity and Metabolism , 22 (1), 123-127.
Choi, H. Y., Kim, Y. H., Kim, M. J., Lee, S. H., Bang, K., Han, S., Lim,
H.-S., & Bae, K.-S. (2014). Evaluation of pharmacokinetic drug
interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and
glimepiride (sulfonylurea) in healthy volunteers. Drugs in R&D ,14 (3), 165-176.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsboll, T. (2009).
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2
diabetes mellitus. IDrugs: the investigational drugs journal ,12 (8), 503-513.
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis,
D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity
Reviews , 20 (6), 805-815.
Clements, J. N., Isaacs, D., Hartman, R. E., & Gambill, K. (2021).
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type
2 Diabetes Mellitus. Clinical Pharmacokinetics , 60 (2),
153-163.
Copley, K., McCowen, K., Hiles, R., Nielsen, L. L., Young, A., &
Parkes, D. G. (2006). Investigation of exenatide elimination and its in
vivo and in vitro degradation. Current drug metabolism ,7 (4), 367-374.
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S.,
Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., & Roell, W. C.
(2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the
treatment of type 2 diabetes mellitus: from discovery to clinical proof
of concept. Molecular metabolism , 18 , 3-14.
Cui, H., Zhao, C.-Y., Lv, Y., Wei, M.-J., Zhu, Y., Ma, X.-Z., Xia,
Y.-H., Tian, J.-H., Ma, Y., & Liu, Y. (2021). Safety, Pharmacokinetics
and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide
(PB-119) in Healthy Volunteers. European Journal of Drug
Metabolism and Pharmacokinetics , 46 (2), 265-275.
Cvetković, R. S., & Plosker, G. L. (2007). Exenatide. Drugs ,67 (6), 935-954.
Damholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M., &
Zdravkovic, M. (2006). An open‐label, parallel group study investigating
the effects of age and gender on the pharmacokinetics of the once‐daily
glucagon‐like peptide‐1 analogue liraglutide. The Journal of
Clinical Pharmacology , 46 (6), 635-641.
Davis, P. N., Ndefo, U. A., Oliver, A., & Payton, E. (2015).
Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for
type 2 diabetes mellitus. American Journal of Health-System
Pharmacy , 72 (13), 1097-1103.
de la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017). No dose
adjustment is recommended for digoxin, warfarin, atorvastatin or a
combination oral contraceptive when coadministered with dulaglutide.Clinical pharmacokinetics , 56 (11), 1415-1427.
Deeks, E. D. (2012). Linagliptin. Drugs , 72 (13),
1793-1824.
Dineen, L., Law, C., Scher, R., & Pyon, E. (2014). Alogliptin (nesina)
for adults with type-2 diabetes. Pharmacy and Therapeutics ,39 (3), 186.
Donate-Correa, J., Luis-Rodríguez, D., Martín-Núñez, E., Tagua, V. G.,
Hernández-Carballo, C., Ferri, C., Rodríguez-Rodríguez, A. E.,
Mora-Fernández, C., & Navarro-González, J. F. (2020). Inflammatory
targets in diabetic nephropathy. Journal of clinical medicine ,9 (2), 458.
Dong, J., Gong, Y., Liu, J., Chen, X., Wen, X., & Sun, H. (2014).
Synthesis and biological evaluation of all eight stereoisomers of DPP-IV
inhibitor saxagliptin. Bioorganic and Medicinal Chemistry ,22 (4), 1383-1393.
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020). Pancreatic β-cells in
type 1 and type 2 diabetes mellitus: different pathways to failure.Nature Reviews Endocrinology , 16 (7), 349-362.
Elkinson, S., & Keating, G. M. (2013). Lixisenatide: first global
approval. Drugs , 73 (4), 383-391.
Evans, K. A., Budzik, B. W., Ross, S. A., Wisnoski, D. D., Jin, J.,
Rivero, R. A., Vimal, M., Szewczyk, G. R., Jayawickreme, C., & Moncol,
D. L. (2009). Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5
receptor agonists. Journal of medicinal chemistry , 52 (24),
7962-7965.
Evans, P. M., & Bain, S. C. (2016). Omarigliptin for the treatment of
type 2 diabetes mellitus. Expert opinion on pharmacotherapy ,17 (14), 1947-1952.
FARES, M., AL-ANI, I., HAILAT, M., KHALEEL, A., COLLIER, P., AL-ANI, A.,
& DAYYIH, W. A. (2021). Evaluation the Impact of Grapefruit Juice on
Sitagliptin Pharmacokinetics in Healthy Rats. International
Journal of Pharmaceutical Research , 13 (2).
Fayyaz, S., Ahmed, D., Khalid, S., Khan, S. N., Shah, M. R., &
Choudhary, M. I. (2020). Synthesis of vildagliptin conjugated metal
nanoparticles for type II diabetes control: targeting the DPP-IV enzyme.New Journal of Chemistry , 44 (47), 20853-20860.
Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W.,
Kassel, D. B., Navre, M., Shi, L., Skene, R. J., & Asakawa, T. (2007).
Discovery of alogliptin: a potent, selective, bioavailable, and
efficacious inhibitor of dipeptidyl peptidase IV. Journal of
medicinal chemistry , 50 (10), 2297-2300.
Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the
glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.Nature Reviews Endocrinology , 15 (10), 569-589.
Frías, J. P. (2020). Tirzepatide: a glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in
development for the treatment of type 2 diabetes. Expert Review of
Endocrinology & Metabolism , 15 (6), 379-394.
[Record #202 is using a reference type undefined in this output
style.]
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X.,
Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020). Efficacy
and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic
peptide and glucagon‐like peptide‐1 receptor agonist in patients with
type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled
study to evaluate different dose‐escalation regimens. Diabetes,
Obesity and Metabolism , 22 (6), 938-946.
Friedrich, C., Ring, A., Brand, T., Sennewald, R., Graefe-Mody, E., &
Woerle, H.-J. (2011). Evaluation of the pharmacokinetic interaction
after multiple oral doses of linagliptin and digoxin in healthy
volunteers. European journal of drug metabolism and
pharmacokinetics , 36 (1), 17-24.
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A.,
Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020).
Pathophysiology of type 2 diabetes mellitus. International journal
of molecular sciences , 21 (17), 6275.
Gao, J., Shi, Z., Zhu, S., Li, G. Q., Yan, R., & Yao, M. (2013).
Influences of processed rhubarbs on the activities of four CYP isozymes
and the metabolism of saxagliptin in rats based on probe cocktail and
pharmacokinetics approaches. Journal of ethnopharmacology ,145 (2), 566-572.
Goda, M., & Kadowaki, T. (2013). Teneligliptin for the treatment of
type 2 diabetes. Drugs of Today (Barcelona, Spain: 1998) ,49 (10), 615-629.
Graefe-Mody, U., Retlich, S., & Friedrich, C. (2012). Clinical
pharmacokinetics and pharmacodynamics of linagliptin. Clinical
pharmacokinetics , 51 (7), 411-427.
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F.
L., Thomsen, M., & Bækdal, T. A. (2019). Safety and pharmacokinetics of
single and multiple ascending doses of the novel oral human GLP-1
analogue, oral semaglutide, in healthy subjects and subjects with type 2
diabetes. Clinical pharmacokinetics , 58 (6), 781-791.
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W.
(2018). Pharmacokinetics, safety and tolerability of oral semaglutide in
subjects with renal impairment. Clinical pharmacokinetics ,57 (12), 1571-1580.
Gu, N., Park, S.-I., Chung, H., Jin, X., Lee, S., & Kim, T.-E. (2020).
Possibility of pharmacokinetic drug interaction between a DPP-4
inhibitor and a SGLT2 inhibitor. Translational and clinical
pharmacology , 28 (1), 17.
Gutch, M., Joshi, A., Kumar, S., Agarwal, A., Pahan, R. K., & Razi, S.
M. (2017). Gemigliptin: newer promising gliptin for type 2 diabetes
mellitus. Indian journal of endocrinology and metabolism ,21 (6), 898.
Habib, H. A., Heeba, G. H., & Khalifa, M. M. (2021). Comparative
effects of incretin-based therapy on early-onset diabetic nephropathy in
rats: Role of TNF-α, TGF-β and c-caspase-3. Life Sciences ,278 , 119624.
Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., Lufft, V., &
Klause, N. (2013). Pharmacokinetics of teneligliptin in subjects with
renal impairment. Clinical pharmacology in drug development ,2 (3), 246-254.
Hall, S., Isaacs, D., & Clements, J. N. (2018). Pharmacokinetics and
clinical implications of semaglutide: a new glucagon-like peptide
(GLP)-1 receptor agonist. Clinical pharmacokinetics ,57 (12), 1529-1538.
He, H., Tran, P., Yin, H., Smith, H., Batard, Y., Wang, L., Einolf, H.,
Gu, H., Mangold, J. B., & Fischer, V. (2009). Absorption, metabolism,
and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4
inhibitor, in humans. Drug metabolism and disposition ,37 (3), 536-544.
He, Y.-L. (2012). Clinical pharmacokinetics and pharmacodynamics of
vildagliptin. Clinical pharmacokinetics , 51 (3), 147-162.
He, Y.-L., Serra, D., Wang, Y., Campestrini, J., Riviere, G.-J., Deacon,
C. F., Holst, J. J., Schwartz, S., Nielsen, J. C., & Ligueros-Saylan,
M. (2007). Pharmacokinetics and pharmacodynamics of vildagliptin in
patients with type 2 diabetes mellitus. Clinical
pharmacokinetics , 46 (7), 577-588.
Hedrington, M. S., & Davis, S. N. (2019). Oral semaglutide for the
treatment of type 2 diabetes. Expert opinion on pharmacotherapy ,20 (2), 133-141.
Herman, G. A., Stevens, C., Van Dyck, K., Bergman, A., Yi, B., De Smet,
M., Snyder, K., Hilliard, D., Tanen, M., & Tanaka, W. (2005).
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of
dipeptidyl peptidase IV, in healthy subjects: results from two
randomized, double‐blind, placebo‐controlled studies with single oral
doses. Clinical Pharmacology and Therapeutics , 78 (6),
675-688.
Hossain, U., Das, A. K., Ghosh, S., & Sil, P. C. (2020). An overview on
the role of bioactive α-glucosidase inhibitors in ameliorating diabetic
complications. Food and Chemical Toxicology , 111738.
Hu, P., Yin, Q., Deckert, F., Jiang, J., Liu, D., Kjems, L., Dole, W.
P., & He, Y. L. (2009). Pharmacokinetics and pharmacodynamics of
vildagliptin in healthy Chinese volunteers. The Journal of
Clinical Pharmacology , 49 (1), 39-49.
Ishiguro, N., Shimizu, H., Kishimoto, W., Ebner, T., & Schaefer, O.
(2013). Evaluation and prediction of potential drug-drug interactions of
linagliptin using in vitro cell culture methods. Drug Metabolism
and Disposition , 41 (1), 149-158.
Jackson, S. H., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F.
(2010). Liraglutide (victoza): the first once-daily incretin mimetic
injection for type-2 diabetes. Pharmacy and Therapeutics ,35 (9), 498.
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016).
Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and
pharmacodynamics. Clinical pharmacokinetics , 55 (6),
657-672.
Jain, L., Chain, A. S., Tatosian, D. A., Hing, J., Passarell, J. A.,
Kauh, E. A., & Lai, E. (2019). Pharmacokinetic–pharmacodynamic
(dipeptidyl peptidase‐4 inhibition) model to support dose rationale in
diabetes patients, including those with renal impairment, for
once‐weekly administered omarigliptin. British journal of clinical
pharmacology , 85 (12), 2759-2771.
Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir,
I., Pedersen, P. J., Rowe, E., Karsbøl, J. D., & Pedersen, M. L.
(2017). Absorption, metabolism and excretion of the GLP-1 analogue
semaglutide in humans and nonclinical species. European Journal of
Pharmaceutical Sciences , 104 , 31-41.
Jensen, L., Kupcova, V., Arold, G., Pettersson, J., & Hjerpsted, J. B.
(2018). Pharmacokinetics and tolerability of semaglutide in people with
hepatic impairment. Diabetes, Obesity and Metabolism ,20 (4), 998-1005.
Kadowaki, T., Haneda, M., Ito, H., Sasaki, K., Matsukawa, M., & Yamada,
Y. (2020). Long-term, real-world safety and efficacy of teneligliptin: a
post-marketing surveillance of more than 10,000 patients with type 2
diabetes in Japan. Advances in therapy , 37 (3), 1065-1086.
Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G.,
Maruyama, N., Nakanishi, N., Gouda, M., Iijima, H., & Watanabe, Y.
(2018). Efficacy and safety of teneligliptin added to canagliflozin
monotherapy in Japanese patients with type 2 diabetes mellitus: A
multicentre, randomized, double‐blind, placebo‐controlled,
parallel‐group comparative study. Diabetes, Obesity and
Metabolism , 20 (2), 453-457.
Kadowaki, T., Seino, Y., Kaku, K., Okamoto, T., Kameya, M., Sato, A.,
Hirano, T., Oshima, N., Gantz, I., & O’Neill, E. A. (2021). A
randomized, placebo‐controlled study to evaluate the efficacy and safety
of adding omarigliptin to insulin therapy in Japanese patients with type
2 diabetes and inadequate glycaemic control. Diabetes, Obesity and
Metabolism , 23 (6), 1242-1251.
Kalhotra, P., Chittepu, V. C., Osorio-Revilla, G., &
Gallardo-Velázquez, T. (2018). Structure–activity relationship and
molecular docking of natural product library reveal chrysin as a novel
dipeptidyl peptidase-4 (dpp-4) inhibitor: An integrated in silico and in
vitro study. Molecules , 23 (6), 1368.
Kang, W. Y., Lee, H. W., Gwon, M.-R., Cho, S., Shim, W.-S., Lee, K.-T.,
Yang, D. H., Seong, S. J., & Yoon, Y.-R. (2020). A Pharmacokinetic Drug
Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.Drug design, development and therapy , 14 , 2101.
Karim, A., Covington, P., Christopher, R., Davenport, M., Fleck, P., Li,
X., Wann, E., & Mekki, Q. (2010). Pharmacokinetics of alogliptin when
administered with food, metformin, or cimetidine: a two-phase, crossover
study in healthy subjects. International journal of clinical
pharmacology and therapeutics , 48 (1), 46-58.
Keating, G. M. (2010). Vildagliptin. Drugs , 70 (16),
2089-2112.
Kim, N., Patrick, L., Mair, S., Stevens, L., Ford, G., Birks, V., &
Lee, S.-H. (2014). Absorption, metabolism and excretion of [14C]
gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.Xenobiotica , 44 (6), 522-530.
Kim, S.-H., Lee, S.-H., & Yim, H.-J. (2013). Gemigliptin, a novel
dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the
history of Korean pharmaceutical industry. Archives of pharmacal
research , 36 (10), 1185-1188.
Kim, S.-H., Yoo, J.-H., Lee, W. J., & Park, C.-Y. (2016). Gemigliptin:
an update of its clinical use in the management of type 2 diabetes
mellitus. Diabetes & metabolism journal , 40 (5), 339-353.
Kinoshita, S., & Kondo, K. (2015). Evaluation of pharmacokinetic and
pharmacodynamic interactions of canagliflozin and teneligliptin in
Japanese healthy male volunteers. Expert Opinion on Drug
Metabolism and Toxicology , 11 (1), 7-14.
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L.,
Fineman, M. S., & Baron, A. D. (2005). Pharmacokinetics,
pharmacodynamics, and safety of exenatide in patients with type 2
diabetes mellitus. American Journal of Health-System Pharmacy ,62 (2), 173-181.
Krishna, R., Addy, C., Tatosian, D., Glasgow, X. S., Gendrano III, I.
N., Robberechts, M., Haazen, W., de Hoon, J., Depré, M., & Martucci, A.
(2016). Pharmacokinetics and pharmacodynamics of omarigliptin, a
once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor, after single and
multiple doses in healthy subjects. The Journal of Clinical
Pharmacology , 56 (12), 1528-1537.
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed,
J., Madsen, K., Knudsen, L. B., McGuire, J., & Steensgaard, D. B.
(2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1)
analogue semaglutide. Journal of medicinal chemistry ,58 (18), 7370-7380.
Lee, B., Shi, L., Kassel, D. B., Asakawa, T., Takeuchi, K., &
Christopher, R. J. (2008). Pharmacokinetic, pharmacodynamic, and
efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl
peptidase-4, in rats, dogs, and monkeys. European journal of
pharmacology , 589 (1-3), 306-314.
Lee, Y.-h., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M.,
& Lee, B.-W. (2017). Lobeglitazone, a novel thiazolidinedione, improves
non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and
predictive factors related to responsiveness. Journal of Korean
medical science , 32 (1), 60-69.
Leiter, L. A., Gómez-Huelgas, R., Ambos, A., Arteaga, J. M., Marchesini,
G., Nikonova, E., Shestakova, M., Stager, W., Tambascia, M., &
Hanefeld, M. (2014). Lixisenatide is effective and well tolerated in
patients with type 2 diabetes mellitus and renal impairment.Canadian Journal of Diabetes , 38 (5), S10-S11.
Li, Q., Deng, X., Jiang, N., Meng, L., Xing, J., Jiang, W., & Xu, Y.
(2021). Identification and structure–activity relationship exploration
of uracil-based benzoic acid and ester derivatives as novel dipeptidyl
Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.European Journal of Medicinal Chemistry , 225 , 113765.
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B.,
Chan, P., & Liu, Z. (2020). An evaluation of liraglutide including its
efficacy and safety for the treatment of obesity. Expert opinion
on pharmacotherapy , 21 (3), 275-285.
Linnebjerg, H., Kothare, P. A., Park, S., Mace, K., Reddy, S., Mitchell,
M., & Lins, R. (2007). Effect of renal impairment on the
pharmacokinetics of exenatide. British journal of clinical
pharmacology , 64 (3), 317-327.
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Landó, L. F., Brown,
K., Bray, R., & Rodríguez, Á. (2021). Once-weekly tirzepatide versus
once-daily insulin degludec as add-on to metformin with or without SGLT2
inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised,
open-label, parallel-group, phase 3 trial. The Lancet ,398 (10300), 583-598.
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H.,
Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen,
A. K. (2010). Metabolism and excretion of the once-daily human
glucagon-like peptide-1 analog liraglutide in healthy male subjects and
its in vitro degradation by dipeptidyl peptidase IV and neutral
endopeptidase. Drug Metabolism and Disposition , 38 (11),
1944-1953.
Mann, J. L., Maikawa, C. L., Smith, A. A., Grosskopf, A. K., Baker, S.
W., Roth, G. A., Meis, C. M., Gale, E. C., Liong, C. S., & Correa, S.
(2020). An ultrafast insulin formulation enabled by high-throughput
screening of engineered polymeric excipients. Science
translational medicine , 12 (550).
[Record #197 is using a reference type undefined in this output
style.]
Mcfarlane, M., Liu, B., & Nwokolo, C. (2018). Domperidone prolongs oral
to duodenal transit time in video capsule endoscopy. European
Journal of Clinical Pharmacology , 74 (4), 521-524.
Migoya, E. M., Stevens, C. H., Bergman, A. J., Luo, W.-l., Lasseter, K.
C., Dilzer, S. C., Davies, M. J., Wagner, J. A., & Herman, G. A.
(2009). Effect of moderate hepatic insufficiency on the pharmacokinetics
of sitagliptin. Journal of Population Therapeutics and Clinical
Pharmacology , 16 (1).
Moon, S. J., Yu, K.-S., & Kim, M.-G. (2020). An assessment of
pharmacokinetic interaction between lobeglitazone and sitagliptin after
multiple oral administrations in healthy men. Clinical
therapeutics , 42 (6), 1047-1057.
Morimoto, K., Sasaki, M., Oikawa, E., Abe, M., Kikuchi, T., Ishii, M.,
Ogihara, T., & Tomita, M. (2021). Intestinal Absorption of Alogliptin
Is Mediated by a Fruit-Juice-Sensitive Transporter. Biological and
Pharmaceutical Bulletin , 44 (5), 653-658.
Morrow, L., Hompesch, M., Guthrie, H., Chang, D., & Chatterjee, D.
(2011). Co‐administration of liraglutide with insulin detemir
demonstrates additive pharmacodynamic effects with no pharmacokinetic
interaction. Diabetes, Obesity and Metabolism , 13 (1),
75-80.
Nakamaru, Y., Hayashi, Y., Ikegawa, R., Kinoshita, S., Madera, B. P.,
Gunput, D., Kawaguchi, A., Davies, M., Mair, S., & Yamazaki, H. (2014).
Metabolism and disposition of the dipeptidyl peptidase IV inhibitor
teneligliptin in humans. Xenobiotica , 44 (3), 242-253.
Nangaku, M., & Wanner, C. (2021). Not only incretins for diabetic
kidney disease—beneficial effects by DPP-4 inhibitors. Kidney
International , 99 (2), 318-322.
Nauck, M. (2016). Incretin therapies: highlighting common features and
differences in the modes of action of glucagon‐like peptide‐1 receptor
agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity
and Metabolism , 18 (3), 203-216.
Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: their role in
health and disease. Diabetes, Obesity and Metabolism , 20 ,
5-21.
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004). Pharmacology of
exenatide (synthetic exendin-4): a potential therapeutic for improved
glycemic control of type 2 diabetes. Regulatory peptides ,117 (2), 77-88.
Noh, Y.-H., Lim, H.-S., Jin, S.-J., Kim, M. J., Kim, Y. H., Sung, H. R.,
Choi, H. Y., & Bae, K.-S. (2012). Effects of ketoconazole and
rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl
peptidase-IV inhibitor: a crossover drug–drug interaction study in
healthy male Korean volunteers. Clinical therapeutics ,34 (5), 1182-1194.
Norris, J. M., Johnson, R. K., & Stene, L. C. (2020). Type 1
diabetes—early life origins and changing epidemiology. The
Lancet Diabetes & Endocrinology , 8 (3), 226-238.
Packer, M. (2021). Differential pathophysiological mechanisms in heart
failure with a reduced or preserved ejection fraction in diabetes.JACC: Heart Failure , 9 (8), 535-549.
Parsa, K. V., & Pal, M. (2011). Preclinical development of dipeptidyl
peptidase IV inhibitor alogliptin: a brief overview. Expert
opinion on drug discovery , 6 (8), 855-869.
Peng, W., Rao, D., Zhang, M., Shi, Y., Wu, J., Nie, G., & Xia, Q.
(2020). Teneligliptin prevents doxorubicin-induced inflammation and
apoptosis in H9c2 cells. Archives of biochemistry and biophysics ,683 , 108238.
Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., &
Meier, J. J. (2020). Effects of lixisenatide versus liraglutide
(short-and long-acting GLP-1 receptor agonists) on esophageal and
gastric function in patients with type 2 diabetes. Diabetes Care ,43 (9), 2137-2145.
Rendell, M. S. (2016). Albiglutide: a unique GLP-1 receptor agonist.Expert opinion on biological therapy , 16 (12), 1557-1569.
Rendell, M. S. (2018). Albiglutide for the management of type 2
diabetes. Expert review of endocrinology & metabolism ,13 (1), 1-8.
Röhrborn, D., Wronkowitz, N., & Eckel, J. (2015). DPP4 in diabetes.Frontiers in immunology , 6 , 386.
Saltiel, A. R., & Olefsky, J. M. (1996). Thiazolidinediones in the
treatment of insulin resistance and type II diabetes. Diabetes ,45 (12), 1661-1669.
Sanford, M. (2014). Dulaglutide: first global approval. Drugs ,74 (17), 2097-2103.
Scheen, A. J. (2017). Dulaglutide for the treatment of type 2 diabetes.Expert opinion on biological therapy , 17 (4), 485-496.
Scott, L. J. (2010). Alogliptin. Drugs , 70 (15), 2051-2072.
Shon, J., Kim, N., Park, S., Oh, M., Kim, E., Lee, S., Kim, Y., & Shin,
J. (2014). Effect of renal impairment and haemodialysis on the
pharmacokinetics of gemigliptin (LC15‐0444). Diabetes, Obesity and
Metabolism , 16 (10), 1028-1031.
Stofella, N. C., Veiga, A., Oliveira, L. J., Montin, E. F., Andreazza,
I. F., Carvalho Filho, M. A., Bernardi, L. S., Oliveira, P. R., &
Murakami, F. S. (2019). Solid-state characterization of different
crystalline forms of sitagliptin. Materials , 12 (15), 2351.
Su, H., Boulton, D. W., Barros, A., Wang, L., Cao, K., Bonacorsi, S. J.,
Iyer, R. A., Humphreys, W. G., & Christopher, L. J. (2012).
Characterization of the in vitro and in vivo metabolism and disposition
and cytochrome P450 inhibition/induction profile of saxagliptin in
human. Drug Metabolism and Disposition , 40 (7), 1345-1356.
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin,
K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021). Dual GIP and
GLP-1 receptor agonist tirzepatide improves beta-cell function and
insulin sensitivity in Type 2 diabetes. The Journal of Clinical
Endocrinology & Metabolism , 106 (2), 388-396.
Trujillo, J. M., & Nuffer, W. (2014). Albiglutide: a new GLP-1 receptor
agonist for the treatment of type 2 diabetes. Annals of
Pharmacotherapy , 48 (11), 1494-1501.
Upreti, V. V., Boulton, D. W., Li, L., Ching, A., Su, H., LaCreta, F.
P., & Patel, C. G. (2011). Effect of rifampicin on the pharmacokinetics
and pharmacodynamics of saxagliptin, a dipeptidyl peptidase‐4 inhibitor,
in healthy subjects. British journal of clinical pharmacology ,72 (1), 92-102.
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O’Farrell, L.,
Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020). The novel
dual glucose‐dependent insulinotropic polypeptide and glucagon‐like
peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays
gastric emptying similarly to selective long‐acting GLP‐1 receptor
agonists. Diabetes, Obesity and Metabolism , 22 (10),
1886-1891.
Urva, S., Quinlan, T., Landry, J., Martin, J., Loghin, C., & Goergens,
S. (2021). Renal impairment has no impact on the clinical
pharmacokinetics of tirzepatide. Diabetologie und Stoffwechsel ,16 (S 01).
Use, C. f. M. P. f. H. (2013). European Medicines Agency. European
Public Assessment Report: procedure no .
van Netten, J. J., Bus, S. A., Apelqvist, J., Lipsky, B. A., Hinchliffe,
R. J., Game, F., Rayman, G., Lazzarini, P. A., Forsythe, R. O., &
Peters, E. J. (2020). Definitions and criteria for diabetic foot
disease. Diabetes/metabolism research and reviews , 36 ,
e3268.
Vincent, S. H., Reed, J. R., Bergman, A. J., Elmore, C. S., Zhu, B., Xu,
S., Ebel, D., Larson, P., Zeng, W., & Chen, L. (2007). Metabolism and
excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin
in humans. Drug metabolism and disposition , 35 (4),
533-538.
Vora, A., Varghese, A., Kachwala, Y., Laddha, A. P., Bhaskar, M.,
Akhtar, J., & Yadav, P. (2020). Pharmacokinetic and pharmacodynamic
interactions of Tinospora cordifolia aqueous extract and hypoglycemic
drugs in streptozotocin-induced diabetes in rats. Pharmacognosy
Magazine , 16 (68), 47.
Weber, A. E., & Thornberry, N. (2007). Case History:
JANUVIA™(Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for
the Treatment of Type 2 Diabetes. Annual Reports in Medicinal
Chemistry , 42 , 95-109.
Werner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010).
Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist
for the treatment of type 2 diabetes. Regulatory peptides ,164 (2-3), 58-64.
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott,
D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman,
C., & Cardona, G. R. (2020). Tirzepatide is an imbalanced and biased
dual GIP and GLP-1 receptor agonist. JCI insight , 5 (17).
Xie, C., Huang, W., Watson, L. E., Soenen, S., Young, R. L., Jones, K.
L., Horowitz, M., Rayner, C. K., & Wu, T. (2021). Plasma GLP-1 response
to oral and intraduodenal nutrients in health and type 2
diabetes–impact on gastric emptying. The Journal of Clinical
Endocrinology & Metabolism .
Xu, G., Liu, B., Sun, Y., Du, Y., Snetselaar, L. G., Hu, F. B., & Bao,
W. (2018). Prevalence of diagnosed type 1 and type 2 diabetes among US
adults in 2016 and 2017: population based study. Bmj , 362 .
Xu, S., Tatosian, D., Mcintosh, I., Caceres, M., Matthews, C., Samuel,
K., Selverian, D., Kumar, S., & Kauh, E. (2018). Absorption, metabolism
and excretion of [14C] omarigliptin, a once-weekly DPP-4 inhibitor,
in humans. Xenobiotica , 48 (6), 584-591.
Yang, L. P. (2012). Saxagliptin. Drugs , 72 (2), 229-248.
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., &
Sahebkar, A. (2020). GLP-1 mimetics and cognition. Life Sciences ,
118645.
Yoon, S. A., Han, B. G., Kim, S. G., Han, S. Y., Jo, Y. I., Jeong, K.
H., Oh, K. H., Park, H. C., Park, S. H., & Kang, S. W. (2017).
Efficacy, safety and albuminuria‐reducing effect of gemigliptin in K
orean type 2 diabetes patients with moderate to severe renal impairment:
A 12‐week, double‐blind randomized study (the GUARD S tudy).Diabetes, Obesity and Metabolism , 19 (4), 590-598.
Yoshikawa, K., Tsuchiya, A., Kido, T., Ota, T., Ikeda, K., Iwakura, M.,
Maeda, Y., & Maekawa, S. (2020). Long-Term Safety and Efficacy of
Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a
Multicentre, Open-Label, Observational Post-Marketing Surveillance
Study. Advances in therapy , 37 (5), 2442-2459.
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J.,
Zhi, H., & Reinhardt, R. R. (2014). Clinical pharmacology of
albiglutide, a GLP-1 receptor agonist. Postgraduate medicine ,126 (7), 84-97.